%0 Journal Article
%T Leukotriene Receptor Antagonist in Treating Allergic Rhinitis; Literature Review
%A Tamim Khalid Alzughaibi
%A Raghad Fuad Alhejaili
%A Ahmad Zaher Ali
%A Abdulrahman Jaber Alfaifi
%A Husam Mohammed Almaramhi
%A Abdulrahman Fahad Alqifari
%A Abdullah Shref Alwthainani
%A Riam Saleh Alkhamis
%A Nasser Tareq Aldosari
%A Bader Ahmad Alshammari
%J Journal of Biochemical Technology
%@ 0974-2328
%D 2021
%V 12
%N 4
%R 10.51847/hg79JzKyou
%P 99-103
%X A type 1 hypersensitivity disorder is Allergic rhinitis that affects the nasal mucosa and is described by frequent attacks of rhinorrhea and sneezing, nasal pruritus, and nasal congestion. It is the most regular disease stated in the ENT clinic and is generally controlled by nasal corticosteroids, vasoconstrictors, oral antihistamines, oral leukotriene receptor antagonists, or a medley of these agents. This study aimed to study the literature on the disease and to evaluate the effectiveness and safeness of leukotriene receptor antagonists compared with other therapeutic agents. We checked the PubMed database and searched for related articles toward the issue. We used the following Mesh words: Leukotriene receptor antagonists, rhinitis, allergic rhinitis, montelukast. The leukotriene (montelukast) receptor antagonist appears to play a restorative role in the treatment of patients with asthma and allergic rhinitis. However, compared with other agents, most current trials reported that montelukast provides greater effect in allergic rhinitis patients than placebo, especially nighttime symptoms, equal effect to antihistamine, and inferior to nasal corticosteroids. Additionally, montelukast, when combined with other agents, seems to provide a greater beneficial effect than monotherapy. 
%U https://jbiochemtech.com/article/leukotriene-receptor-antagonist-in-treating-allergic-rhinitis-literature-review-2haw6jbg7kaw6hy